



Dear Healthcare Professional,

Topotarget A/S  
Symbion Science Park  
Fruebjergvej 3  
DK-2100 Copenhagen  
Denmark

[www.topotarget.com](http://www.topotarget.com)

Phone +45 3917 8392  
Fax +45 3917 9492  
CVR-nr 2569 5771  
VAT-no DK 2569 5771

Effective October 4, 2010, Topotarget is offering oncology infusion centers the opportunity to participate in a test market for Totect® Urgent Treatment Kit. The test market participants will be eligible to purchase Totect® from one of our authorized distributors (<http://totect.com/PDF/Ordering.pdf>) at \$6,500 and receive one replacement kit, should the kit expire before use. Totect® has a shelf life of 24 months from the date of manufacturing. Product at our authorized distributors currently has a shelf life of 16 to 19 months.

Totect® (dexrazoxane for injection) is packaged in an Urgent Treatment Kit for single patient use and includes 10 vials of Totect® powder 500mg each and 10 vials of Totect® diluent 50mL each. Totect® is indicated for the treatment of extravasation resulting from intravenous anthracycline chemotherapy. Totect® demonstrated 98.2%<sup>1</sup> efficacy based on two biopsy-confirmed clinical trials and should be proactively stocked onsite and infused as soon as possible and within six hours of an anthracycline extravasation.

It is important to note that there is no generic to Totect® for the treatment of anthracycline extravasation. Totect is the only FDA approved product for the treatment of anthracycline extravasation.

Topotarget Regional Business Managers (RBM) are deployed strategically throughout the country to provide immediate assistance should you experience an anthracycline extravasation, conduct in-service training programs, etc. Topotarget also has a dedicated anthracycline extravasation Medical Hotline (866) 914-2922 and offers reimbursement and other educational support through our website at [www.Totect.com](http://www.Totect.com). In addition, Topotarget provides grants for continuing education programs live and web-based ([www.mlicme.org/P09019.html](http://www.mlicme.org/P09019.html)) that have yielded over 4,100 participants. Only Topotarget can provide you with these services as we have the only FDA approved product for the treatment of anthracycline extravasation.

Totect® was approved by the FDA in September 2007 and is designated as an Orphan Drug. Since launch, Totect® has been adopted by many facilities, both institutional and private practice/community cancer centers, for treating anthracycline extravasations.

Anthracycline extravasations occur when an anthracycline chemotherapy infusion leaks out of a vein (whether peripheral or port access) into the surrounding healthy tissue. The symptoms of an anthracycline extravasation may include, but not limited to, redness, pain and swelling followed by blistering, tissue necrosis and possible surgical debridement. If surgical debridement is required, the patient is forced to postpone his or her chemotherapy treatment until the surgical wound heals. The costs to a facility associated with an anthracycline extravasation prior to the availability of Totect® included extended hospital stay, surgical debridement and possible long term rehabilitation as well as any litigation that may follow. The cost to the patient is the human toll of pain and suffering and postponement of cancer treatment.

Totect® was approved by the FDA based on two biopsy-confirmed clinical trials where 98.2% of patients treated with Totect®, as soon as possible and within six hours of an anthracycline extravasation, did not require surgical debridement. In addition, 71%<sup>1</sup> of the patients treated with Totect® continued with their next scheduled chemotherapy infusion without delay.

Since 2008, professional oncology nursing societies have updated their guidelines to include Totect® for the treatment of extravasation resulting from intravenous anthracycline chemotherapy. In October 2008, extravasation of vesicant chemotherapy was assigned an ICD-9 code of 999.81. Also in 2009, extravasation management was included as a chemotherapy administration safety standard. If you have not reviewed your extravasation policies and procedures, now is a good time.

Topotarget is proud to have served the worldwide oncology community for over 10 years. It is our mission to continue to research and develop novel treatments in both the therapeutic and supportive care categories in providing answers for cancer.

For further information, please see full prescribing information at ([www.totect.com/PDF/Prescribing\\_Information.pdf](http://www.totect.com/PDF/Prescribing_Information.pdf)) or visit our website at [www.Totect.com](http://www.Totect.com).

If you have any questions, you may contact your **Topotarget Regional Business Manager, or call us at 866.470.8274.**

Sincerely,

John L. Parsons, Jr.  
Chief Commercial Officer Topotarget A/S  
President Topotarget USA

<sup>1</sup>: Mouridsen HT et al. *Treatment of anthracycline extravasation with savene (dexrazoxane). Results from two prospective clinical multicentre studies.* Ann Oncol 2007; 18:546-550.

Contraindications: None. Warnings and Precautions: Totect® is a cytotoxic drug. Myelosuppression: Dexrazoxane is associated with leukopenia, neutropenia, and thrombocytopenia. Perform hematological monitoring. Use In Pregnancy: Pregnancy Category D. Fetal harm can occur when administered to a pregnant woman. Advise women of potential harm to the fetus. Adverse Reactions: the most common adverse reactions (>16%) are nausea, pyrexia, injection site pain and vomiting. Drug Interactions: Dimethylsulfoxide. Based on anecdotal reports concurrent use of topical dimethylsulfoxide (DMSO) at the site of tissue injury may reduce the benefit of Totect. Use in Specific Populations: Nursing Mothers: Discontinue drug or nursing, taking into consideration the importance of drug to the mother. Renal impairment: Reduce the Totect dose by 50% in patients with creatinine clearance values <40 mL/min.